NeoDiagnostix Inc. Announces Issuance of Third US Patent

June 12, 2014

NeoDiagnostix, Inc. announced today that the United States Patent and Trademark Office has issued US Patent No. 8,748,099 covering the detection of chromosomal abnormalities in cervical samples. The patent covers methods for enumerating chromosomal copy number at location 3q, as well as other loci in the genome of cells from cervical samples.

“We are very pleased with the achievement of this most recent milestone” said Richard M. Pinnola, President and CEO of NeoDiagnostix. “We believe that our intellectual property portfolio represents a key value driver for the company. The issuance of our newest patent further strengthens our leadership position for the detection of chromosomal abnormalities in cells from cervical samples as identified by our proprietary Cervical DNA Dtex® test.”

The Cervical DNA Dtex® test is a fluorescence in situ hybridization (FISH) test that identifies chromosomal abnormalities as defined by multiple copies of 3q and/or 5p in cervical cells, a hallmark of cervical carcinoma The Cervical DNA Dtex® test identifies the permanent and irreversible damage to cervical cell DNA as the result of persistent human papilloma virus (HPV) infection. Normal cervical cells have 2 copies of chromosomal regions 3q and 5p. Persistent HPV infection leads to genomic instability and the gain of extra copies at regions 3q and/or 5p. Mild abnormalities, such as the presence of cervical intraepithelial neoplasia (CIN2), include a few extra copies of these chromosomal regions in the DNA of the cervical cells. As the disease progresses toward carcinoma, more serious abnormalities occur and can result in a multitude of extra copies of 3q and 5p.

About NeoDiagnostix, Inc.

NeoDiagnostix, located in Rockville, MD, is a leading provider of fluorescence in situ hybridization (FISH) testing for cervical and other cancers. Identification of chromosomal abnormalities in clinical samples has long been associated with the development and progression of various cancers. The company’s flagship test, the Cervical DNA Dtex® test, identifies the permanent and irreversible damage to cervical cells as the result of persistent HPV infection.

Contact

NeoDiagnostix, Inc.
Richard M. Pinnola
President and CEO
240.821.6001
rich.pinnola@neodiagnostix.com